文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

接受单倍体相合异基因移植的重型再生障碍性贫血患者死亡预测评分系统的开发与验证

Development and validation of a mortality predicting scoring system for severe aplastic anaemia patients receiving haploidentical allogeneic transplantation.
PubMed 文献 · Br J Haematol · 2021-11-06

该回顾性研究纳入2006至2020年间接受单倍体相合异基因造血干细胞移植(haplo-HSCT)的432例重型再生障碍性贫血(SAA)患者,随机分为训练集(n=288)和验证集(n=144)。基于诊断至移植时间、ECOG状态和HCT-CI评分构建haplo-HSCT评分系统,训练集中低、中、高危组3年治疗相关死亡率(TRM)分别为6%、21%和47%(P<0.0001),验证集中中危组(HR 2.45,95%CI 0.92-6.53)和高危组(HR 11.74,95%CI 3.07-44.89)较低危组TRM风险升高(P=0.001)。结论认为该评分系统可有效预测移植后TRM。

要点

  • 基于诊断至移植时间、ECOG状态和HCT-CI评分构建haplo-HSCT评分系统。
  • 训练集中低、中、高危组3年TRM分别为6%、21%、47%(P<0.0001)。
  • 验证集中中危组HR 2.45(95%CI 0.92-6.53),高危组HR 11.74(95%CI 3.07-44.89)(P=0.001)。

核心结论

  • haplo-HSCT评分系统可有效预测SAA患者移植后治疗相关死亡率。

研究设计与样本

  • 回顾性研究,使用本中心数据库,纳入2006至2020年间接受haplo-HSCT的432例SAA患者,随机分为训练集(n=288)和验证集(n=144)。

主要发现

  • 训练集多因素模型显示,较长的诊断至移植时间、较差的ECOG状态和较高的HCT-CI评分是治疗相关死亡率(TRM)较差的独立危险因素。
  • 训练集中低、中、高危组3年TRM分别为6%(95%CI 1-21%)、21%(95%CI 7-40%)和47%(95%CI 20-70%)(P<0.0001)。
  • 验证集中,中危组较高危组?

关键数值与推荐

  • haplo-HSCT评分系统由诊断至移植时间、ECOG状态和HCT-CI评分三个参数构建。
  • 训练集3年TRM:低危组6%(95%CI 1-21%),中危组21%(95%CI 7-40%),高危组47%(95%CI 20-70%)(P<0.0001)。
  • 验证集中危组HR 2.45(95%CI 0.92-6.53),高危组HR 11.74(95%CI 3.07-44.89),均与低危组比较(P=0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Haploidentical allogeneic haematopoietic stem cell transplantation (haplo-HSCT) is a significant alternative treatment for severe aplastic anaemia (SAA). To improve this process by modifying the risk stratification system, we conducted a retrospective study using our database. 432 SAA patients who received haplo-HSCT between 2006 and 2020 were enrolled. These patients were divided into a training (n = 288) and a validation (n = 144) subset randomly. In the training cohort, longer time from diagnosis to transplantation, poorer Eastern Cooperative Oncology Group (ECOG) status and higher haematopoietic cell transplantation-specific comorbidity index (HCT-CI) score were independent risk factors for worse treatment-related mortality (TRM) in the final multivariable model. The haplo-HSCT scoring system was developed by these three parameters. Three-year TRM after haplo-HSCT were 6% [95% confidence interval (CI), 1-21%], 21% (95% CI, 7-40%), and 47% (95% CI, 20-70%) for the low-, intermediate-, and high-risk group, respectively (P < 0·0001). In the validation cohort, the haplo-HSCT scoring system also separated patients into three risk groups with increasing risk of TRM: intermediate-risk [hazard ratio (HR) 2·45, 95% CI, 0·92-6·53] and high-risk (HR 11·74, 95% CI, 3·07-44·89) compared with the low-risk group (P = 0·001). In conclusion, the haplo-HSCT scoring system could effectively predict TRM after transplantation.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Xu LP, Yu Y, Cheng YF, et al. Development and validation of a mortality predicting scoring system for severe aplastic anaemia patients receiving haploidentical allogeneic transplantation. Br J Haematol. 2021. PMID: 34741461. doi:10.1111/bjh.17916

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。